Evidence map›Paper›PMID 33431618›Full record

ArticleOpen heart2021

Management of patients with severe aortic stenosis in the TAVI-era: how recent recommendations are translated into clinical practice.

Alexander Lauten, Tanja K Rudolph, David Messika-Zeitoun, Jeetendra Thambyrajah, Antonio Serra, Eberhard Schulz, Norbert Frey, Jiri Maly, Marco Aiello, Guy Lloyd and 15 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Open heart, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Observational
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 20 institutions in 10 countries.

Alexander LautenDepartment for Cardiology, Helios Clinic, Erfurt, Germany.
Tanja K RudolphDepartment of Cardiology, Hear and Diabetes Center Bad Oeynhausen, Ruhr-University of Bochum, Bad Oeynhausen, Germany.
David Messika-ZeitounUniversity of Ottawa Heart Institute, Ottawa, Ontario, Canada.ORCID 0000-0002-6278-5670
Jeetendra ThambyrajahJames Cook University Hospital, Middlesbrough, UK.
Antonio SerraInterventional Cardiology Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Catalunya, Spain.
Eberhard SchulzCardiology Department, AKH Celle, Celle, Niedersachsen, Germany.
Norbert FreyDepartment of Cardiology and Angiology, University of Kiel, Kiel, Schleswig-Holstein, Germany.
Jiri MalyDepartment of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Marco AielloDepartment of Cardiothoracic Surgery, Foundation IRCCS Policlinico S.Matteo, Pavia, Italy.
Guy LloydSt Bartholomew's Hospital, London, UK.
Alessandro Santo BortoneUniversity of Bari, Bari, Puglia, Italy.
Alberto ClericiUniversity of Turin, Turin, Piemonte, Italy.
Georg Delle-Karth4th Medical Department, Hietzing Hospital, Vienna, Austria.
Johannes RieberHerzkatheterlabor Nymphenburg and Department of Cardiology, University of Munich, Munich, Bayern, Germany.
Ciro IndolfiDivision of Cardiology and URT CNR of IFC, University Magna Graecia, Catanzaro, Calabria, Italy.
Massimo ManconeSapienza University of Rome, Rome, Italy.
Loic BelleCentre Hospital d'Annecy, Annecy, France.
Martin ArnoldDepartment of Cardiology, University Hospital Erlangen, Erlangen, Bayern, Germany.
Berto J BoumaUniversity of Amsterdam, Amsterdam, Netherlands.
Matthias LutzDepartment of Cardiology and Angiology, University of Kiel, Kiel, Schleswig-Holstein, Germany.
Cornelia DeutschInstitut für Pharmakologie und Präventive Medizin GmbH, Cloppenburg, Germany.
Jana KurucovaEdwards Lifesciences, Prague, Czech Republic.
Martin ThoenesEdwards Lifesciences, Nyon, Switzerland.
Peter BramlageInstitut für Pharmakologie und Präventive Medizin GmbH, Cloppenburg, Germany peter.bramlage@ippmed.de.ORCID 0000-0003-4970-2110
Richard Paul SteedsQueen Elizabeth Hospital & Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.ORCID 0000-0001-5687-2535
Christian-Albrechts-Universität zu Kiel · DEIPPMed (Germany) · DEAmsterdam University of the Arts · NLBayer (Germany) · DECentre Hospitalier Annecy Genevois · FRCharles University · CZEdwards Lifesciences (Switzerland) · CHHeart and Diabetes Center North Rhine-Westphalia · DEHelios Klinikum Erfurt · DEHospital de Sant Pau · ESInstitute of Pathology Celle · DEJames Cook University Hospital · GBKlinik Hietzing · ATMagna Graecia University · ITPoliclinico San Matteo Fondazione · ITQueen Elizabeth Hospital Birmingham · GBSapienza University of Rome · ITSt Bartholomew's Hospital · GBUniversitätsklinikum Erlangen · DEUniversity of Bari Aldo Moro · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveApproximately 3.4% of adults aged >75 years suffer from aortic stenosis (AS). Guideline indications for aortic valve replacement (AVR) distinguish between patients with symptomatic and asymptomatic severe AS. The present analysis aims to assess contemporary practice in the treatment of severe AS across Europe and identify characteristics associated with treatment decisions, namely denial of AVR in symptomatic patients and assignment of asymptomatic patients to AVR.

methodsParticipants of the prospective, multinational IMPULSE database of patients with severe AS were grouped according to AS symptoms, and stratified into subgroups based on assignment to/denial of AVR.

resultsOf 1608 symptomatic patients, 23.8% did not undergo AVR and underwent medical treatment. Denial was independently associated with multiple factors, including severe frailty (p=0.024); mitral (p=0.002) or tricuspid (p=0.004) regurgitation grade III/IV, and the presence of renal impairment (p=0.017). Of 392 asymptomatic patients, 86.5% had no prespecified indication for AVR. Regardless, 36.3% were assigned to valve replacement. Those with an indexed aortic valve area (AVA; p=0.045) or left ventricular ejection fraction (LVEF; p<0.001) below the study median; or with a left ventricular end systolic diameter above the study median (p=0.007) were more likely to be assigned to AVR.

conclusionsThere may be considerable discrepancies between guideline-based recommendations and clinical practice decision-making in the treatment of AS. It appears that guidelines may not fully capture the complete clinical spectrum of patients with AS. Thus, there is a need to find ways to increase their acceptance and the rate of adoption.

Indexed as

Disease ManagementPractice Guidelines as TopicQuality of Health CareAgedAortic Valve StenosisEchocardiographyFemaleFollow-Up StudiesHumansMaleProspective StudiesSeverity of Illness IndexTranscatheter Aortic Valve Replacementaortic valve stenosiscardiac surgical procedurestranscatheter aortic valve replacement

Identifiers

PMID33431618
PMCPMC7802661
OpenAlexW3118607347

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.